RXRX vs. KYMR, SDGR, RCUS, PTCT, VIE, PCVX, RVMD, EXEL, HALO, and CRSP
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Kymera Therapeutics (KYMR), Schrödinger (SDGR), Arcus Biosciences (RCUS), PTC Therapeutics (PTCT), Viela Bio (VIE), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), and CRISPR Therapeutics (CRSP). These companies are all part of the "medical" sector.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Kymera Therapeutics received 20 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 51.22% of users gave Recursion Pharmaceuticals an outperform vote while only 48.81% of users gave Kymera Therapeutics an outperform vote.
Recursion Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500.
Kymera Therapeutics has a net margin of -194.67% compared to Recursion Pharmaceuticals' net margin of -765.90%. Kymera Therapeutics' return on equity of -31.92% beat Recursion Pharmaceuticals' return on equity.
Kymera Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Recursion Pharmaceuticals currently has a consensus price target of $14.33, suggesting a potential upside of 68.43%. Kymera Therapeutics has a consensus price target of $42.70, suggesting a potential upside of 29.55%. Given Recursion Pharmaceuticals' higher possible upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Kymera Therapeutics.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 14 mentions for Recursion Pharmaceuticals and 9 mentions for Kymera Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 1.12 beat Kymera Therapeutics' score of 0.76 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.
Summary
Kymera Therapeutics beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
